Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...
SHE: 002773
Kanghong Pharma Wins NMPA Approval for KH617 in Glioblastoma Trial
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...
Chengdu Kanghong’s KH607 Approved for Clinical Trials in Postpartum Depression
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has announced that it has received...
Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial
China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...
Chengdu Kanghong Gains NMPA Approval for KH815 in Advanced Solid Tumors
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has received clinical trial approval from...
Kanghong Pharmaceutical’s NASH Drug KH629 Approved for Clinical Trials in China
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...
Kanghong Pharmaceutical’s NASH Drug KH629 Receives Clinical Trial Implicit Approval in China
On October 18th, the official website of the Center for Drug Evaluation (CDE) of the...
Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...
Chengdu Kanghong Pharmaceutical Gets US FDA Nod for Clinical Trial of KH658 for Wet AMD
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a leading pharmaceutical company based in China,...
Chengdu Kanghong Pharmaceutical’s KH629 Receives FDA Approval for NASH Clinical Trial
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a China-based pharmaceutical company, has announced that...
Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received...
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Kanghong’s Escitalopram Oral Solution Receives NMPA Marketing Approval
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving marketing approval from...
Kanghong Pharma Receives FDA Approval for KH631 Gene Therapy Trial
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approval...
Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...